Clinical Trial Update: Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, and preliminary efficacy of Rhenium-186 NanoLiposomes (186RNL) in glioma patients who previously received 186RNL; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Rhenium-186 NanoLiposomes (Rhenium-186 NanoLiposomes)

Snippet

Sponsor: Plus Therapeutics | Conditions: Glioma | Phase 1 | Status: RECRUITING